A prospective study of detorubicin in malignant mesothelioma.
Between January 1981 and December 1983, a prospective therapeutic trial of detorubicin (14-diethoxyacetoxy-daunorubicin [DTR]) was conducted in 40 patients with histologically proven malignant mesothelioma (MM). DTR was given intravenously at 40 mg/m2 on days 1, 2, and 3 for five 21-day cycles, then 40 mg/m2 once every 21 days. Thirty-five patients (32 with pleural MM, 3 with peritoneal MM) were eligible. The overall median survival from onset of chemotherapy was 17 months. Complete relief from chest pain was observed in 8 of 15 cases (53%). Of 21 patients with measurable disease, there were 2 complete responses (10%) and 7 partial responses (33%). Median duration of response was 30 weeks. Congestive cardiac failure developed in two patients after 1100 and 1600 mg/m2 of DTR, respectively. Hematologic toxicity was moderate. This study demonstrates that DTR is effective against MM.
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D001853:Bone Marrow / Q000187:drug effects; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011446:Prospective Studies; D014839:Vomiting / Q000139:chemically induced
C017218:detorubicin; D003630:Daunorubicin